Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Lincoln Pharmaceuticals Limited

NSE: LINCOLNPharmaceuticals

Share price

₹558.30

-0.61% close of 9 Oct 2026

Market cap ₹1,117 CrP/E 11.6

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

71

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹1,117 Cr

P/E ratio

11.6

P/B ratio

1.5

ROCE

16.3%

ROE

12.3%

Dividend yield

0.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹760.0052-week low ₹444.20

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.2% over the past year, and 12.2% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 18.3% to 14.6% over the last four years.

Whether it grew faster than its sector

It grew 12.2% a year against a sector median of 13.1% — 0.9 percentage points slower.

Room to re-rate, or risk of de-rating

At 11.6× earnings against a market that pays 24.1× across 2199 companies we can price. Its own industry sits at 31.2×, across 5 companies. It is against its own five-year median of 12.6×, the 34th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.7 times its growth rate, on earnings growth of 7%.

Profit growthPrice per ₹1 profitPer 1% growth
Lincoln Pharmaceuticals Limited — this one7%/yr11.6×₹1.7
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9
Dr Reddy's Laboratories-4%/yr31.2×—
Mankind Pharma Limited17%/yr45.5×₹2.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 53 of 130 on returns, 59 of 127 on growth, 80 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 16.3% on capital, ahead of 59% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹377 crore of cash from the business, spent ₹140 crore on plant and equipment, and returned ₹18 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 104 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 113 days for its cash to waiting 239 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 9 checks clear · 100%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 13 Aug 2026 · Consolidated · Unaudited

Revenue

₹177 Cr

Revenue vs last year

+15.1%

Revenue vs last quarter

-5.2%

Net profit

₹36 Cr

Profit vs last year

+29.4%

Profit vs last quarter

+202.0%

Net margin

20.4%

EPS

₹18.09

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹1,117 Cr
Prev close
₹558.30
52w High
₹770
52w Low
₹440
Enterprise value
₹879 Cr
Beta
0.9
Price CAGR 1y
8.0%
Price CAGR 3y
4.0%
Price CAGR 5y
7.0%
Price CAGR 10y
9.0%

Ratios

Return on assets
9.9%
PEG ratio
1.7
P/E ratio
11.6
P/B ratio
1.5
EV / EBITDA
8.7
Industry P/E
37.6
ROCE
16.3%
ROCE 5y average
20.2%
ROE
12.3%
Debt / Equity
0.0
Interest coverage
117.0
Dividend yield
0.3%
ROE 3y average
14.0%
ROE last year
12.0%

Annual P&L

Annual revenue
₹671 Cr
Annual profit
₹88 Cr
Operating margin
15.0%
Net profit margin
13.1%
EBITDA margin
14.6%
Sales growth 3y
9.6%
Sales growth 5y
9.6%
Profit growth 3y
7.0%
Profit growth 5y
7.0%
EPS
₹43.9
Sales growth TTM
10.0%
Profit growth TTM
12.0%
Dividend payout
4.0%

Quarter P&L

Sales latest quarter
₹177 Cr
Profit latest quarter
₹36 Cr
YoY quarterly sales growth
15.1%
YoY quarterly profit growth
28.6%
OPM latest quarter
15.5%

Balance Sheet

Book Value
₹379
Face Value
₹10.0
Total debt
₹4 Cr
Total cash
₹33 Cr
Borrowings
₹4 Cr
Reserves / Equity
36.9

Cash Flow

Operating cash flow
₹106 Cr
Free cash flow
₹82 Cr
FCF yield
7.3%
Net cash flow
₹8 Cr

Shareholding

Promoter holding
49.8%
FII holding
4.6%
DII holding
0.3%
Public holding
45.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,787.0033.94,28,7610.902,901.26.015,299.910.520.5
Divi's Lab.9,548.5085.02,53,4830.31902.065.53,080.027.822.0
Torrent Pharma.4,709.3080.31,79,1270.81566.05.84,921.054.915.2
Zydus Lifesci.1,144.3023.41,14,1440.09990.2-35.18,017.022.021.1
Laurus Labs2,043.70101.01,10,4240.10362.1125.52,026.329.117.8
Cipla1,325.7529.91,07,1030.98785.6-39.27,119.32.315.5
Mankind Pharma2,470.1047.81,02,0260.04574.129.64,030.612.913.5
Lincoln Pharma.561.8511.71,1250.3236.230.9177.315.116.3
Median415.1034.72,1640.0713.229.6162.418.615.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales136156146142147161147168154163166187177
Expenses115125117124125133123141130138143162150
Material Cost546157487459
Change in Inventories11-7.42-2.183.25-1.105.63
Purchases of Stock-in-Trade151622251621
Employee Cost283230313233
Other Expenses342931364131
Operating Profit21313018232824272425242527
OPM %15202013151816161516141315
Other Income8911710109-715715-424
Exceptional items (within Other Income)000000
Interest0000001000000
Depreciation3333333334444
Profit before tax25373822293529163529351748
Tax %25252616202428292231183024
Net Profit19282819242621122820291236
EPS in Rs9.4914149.291213105.78149.98145.8118
Diluted EPS in Rs5.78149.98145.8118

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales266400360361366386424472510581623671694
Expenses240359313308299321337376421480522573593
Material Cost214240
Change in Inventories8.84-7.44
Purchases of Stock-in-Trade6979
Employee Cost112125
Other Expenses118137
Operating Profit26414753686687969010010298101
OPM %10101315181721201817161515
Other Income77255115102234223342
Exceptional items (within Other Income)00
Interest810754221211.8811
Depreciation55667788911131415
Profit before tax2033374662678496100122109116128
Tax %242825252223262827242524
Net Profit15242835495162697393828896
EPS in Rs9.20151417242631353647414448
Diluted EPS in Rs4144
Dividend Payout %1179966544444

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
5%
5 years
10%
3 years
10%
TTM
10%

Compounded profit growth

10 years
14%
5 years
7%
3 years
7%
TTM
12%

Stock price CAGR

10 years
9%
5 years
7%
3 years
4%
1 year
8%

Return on equity

10 years
16%
5 years
15%
3 years
14%
Last year
12%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161620202020202020202020
Reserves95124172204249293346413482573652738
Borrowings76786461345122104
Other Liabilities705648626371859983106125128
Minority Interest00
Total Liabilities258275305347366389452534587700797890
Fixed Assets6698103117121123111132151179182191
CWIP3370202167345
Investments0010111834819791139174209
Other Assets190174186219225232259290339379437486
Total Assets258275305347366389452534587700797890

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity2545252753756976396393106
Cash from Investing Activity7-42-25-12-18-31-64-78-37-57-79-98
Cash from Financing Activity-32-30-11-36-38-6-3-4-5-60
Net Cash Flow-1-0-03-17-1-4-2188
Free Cash Flow21117173868613126247482

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1637392111122969890981029788
Inventory Days443663867595861211061019994
Days Payable92405482921021051207795106100
Cash Conversion Cycle116701001151068878911261089082
Working Capital Days76316989113126119113121121116239
ROCE %152119192322252422221716

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters515050505050505050505050
FIIs2.593.223.933.955.195.1655.134.734.705.204.60
DIIs00.060.050.040000.010.010.011.080.27
Public474746464545454545464445
No. of Shareholders28,67029,31631,37529,96731,33031,84831,86731,78432,37031,02628,30329,396

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +6.0% (₹526.85 → ₹558.30)Brick size ₹18.28 (fixed)Bricks 42
₹500₹600₹700₹558Dec '25Feb '26Apr '26Jun '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹558.30 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-238inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Lincoln Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Caroverine API (for Tinnex Injection)
  • Cephalosporin intermediates (7-ACA, 7-ADCA, GCLE)
  • Key Starting Materials / chemical intermediates for APIs
  • Packaging materials (PVC blisters, aluminium foil, HDPE containers, glass vials, ampoules)
  • Pharmaceutical excipients (MCC, lactose, starch, talc, binders)

Exports to

  • Africa (East and West)
  • Australia
  • Canada
  • Europe
  • Latin America
  • Southeast Asia

sources raw material from

  • Phafag AG · Caroverine API
  • Undisclosed Chinese API/intermediate manufacturers · Cephalosporin intermediates (7-ACA, 7-ADCA, GCLE)
  • Undisclosed Chinese chemical manufacturers · KSMs for benzodiazepine, anticholinergic, anaesthetic, and antispasmodic APIs

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE405C01035

Plants

  • Khatraj Formulation Plant
  • Mehsana Cephalosporin Plant

News impact

Big market events that reach Lincoln Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

11 Sep 2026unspecified₹1.8
12 Sep 2025unspecified₹1.8
13 Sep 2024unspecified₹1.8
15 Sep 2023unspecified₹1.5
15 Sep 2022unspecified₹1.5
16 Sep 2021unspecified₹1.5
5 Mar 2020interim₹1.5
19 Sep 2019unspecified₹1.5

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
29 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY2,08,466₹707.51
29 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL2,08,466₹707.93
29 Apr 2026QE SECURITIES LLPBUY1,09,936₹701.46
29 Apr 2026QE SECURITIES LLPSELL1,06,989₹709.28

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.